Thermo Fisher Scientific Human FGF-basic (FGF-2/bFGF) Recombinant Protein

Applications

Tested Dilution

Publications

Western Blot (WB)

Assay-dependent

-

ELISA (ELISA)

Assay-dependent

-

Immunoprecipitation (IP)

Assay-dependent

-

Miscellaneous PubMed (Misc)

-

View 2 publications 2 publications

Product Specifications

Species

Human

Published species

Not Applicable

Expression System

E. coli

Amino acid sequence

AAGSITTLPA LPEDGGSGAF PPGHFKDPKR LYCKNGGFFL RIHPDGRVDG VREKSDPHIK LQLQAEERGV VSIKGVCANR YLAMKEDGRL LASKCVTDEC FFFERLESNN YNTYRSRKYT SWYVALKRTG QYKLGSKTGP GQKAILFLPM SAKS

Molecular weight

17 kDa

Class

Recombinant

Type

Protein

Activity

ED50 ≤ 0.1 ng/mL; determined by the dose-dependent proliferation of Balb/c 3T3 cells.

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Lyophilized

Purification

purified

Storage buffer

TBS

Contains

no preservative

Storage conditions

-20° C, Avoid Freeze/Thaw Cycles

Shipping conditions

Wet ice

Product Specific Information

For dilution, use a buffer containing carrier protein, e.g. PBS with 1% BSA or a neutral media containing 10% FCS and freeze in aliquots at -70°C.

Reconstitute to 100 µg/mL using distilled water.

Target Information

FGF2 (FGFb, fibroblast growth factor basic) belongs to the fibroblast growth factor (FGF) family, and interacts with high-affinity transmembrane receptors to influence cell proliferation and tissue neovascularization. FGF2 exists as five isoforms with distinct intracellular localizations and functions. The 18 kDa isoform is predominantly cytosolic and acts through cell surface receptors, whereas the 22, 22.5, 24 and 34 kDa isoforms are nuclear and may signal independent of transmembrane receptor pathways. In humans, the gene is located on the q arm of chromosome 4. FGF2 has been implicated in diverse biological processes, such as limb and nervous system development, wound healing, and tumor growth. The mRNA for FGF2 contains multiple polyadenylation sites, and is alternatively translated from non-AUG and AUG initiation codons, resulting in five different isoforms with distinct properties. The CUG-initiated isoforms are localized in the nucleus and are responsible for the intracrine effect, whereas, the AUG-initiated form is mostly cytosolic and is responsible for the paracrine and autocrine effects of this FGF. Diseases associated with FGF2 dysfunction include Kaposi Sarcoma and corneal neovascularization.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.